Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 738.02M P/E - EPS this Y -18.60% Ern Qtrly Grth -
Income -100.84M Forward P/E -5.13 EPS next Y -11.10% 50D Avg Chg 2.00%
Sales 20.72M PEG 0.49 EPS past 5Y - 200D Avg Chg 15.00%
Dividend N/A Price/Book 2.52 EPS next 5Y -15.90% 52W High Chg -32.00%
Recommedations 1.70 Quick Ratio 15.21 Shares Outstanding 51.16M 52W Low Chg 236.00%
Insider Own 3.54% ROA -23.45% Shares Float 31.97M Beta 2.86
Inst Own 86.14% ROE -37.41% Shares Shorted/Prior 9.83M/8.50M Price 17.89
Gross Margin 53.00% Profit Margin - Avg. Volume 551,431 Target Price 52.20
Oper. Margin 192,905.26% Earnings Date May 8 Volume 396,220 Change 0.39%
About 4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

4D Molecular Therapeutics, Inc. News
05/01/24 4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
05/01/24 4DMT Announces Presentations at ARVO 2024 Annual Meeting
04/04/24 4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott Bizily Sells 8,153 Shares
03/29/24 4D Molecular Therapeutics Inc's Chief Legal Officer Sells Company Shares
03/28/24 4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
03/04/24 4DMT to Participate in Upcoming Investor Conferences
03/03/24 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
08:55 AM 4D Molecular Therapeutics Full Year 2023 Earnings: Misses Expectations
04:32 AM 4D Molecular Therapeutics Inc Reports Full Year 2023 Financial Results
02/29/24 4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Misses Revenue Estimates
02/29/24 4DMT Reports Full Year 2023 Financial Results and Operational Highlights
02/26/24 Strength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength?
02/12/24 4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
02/12/24 Institutional investors in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) lost 11% last week but have reaped the benefits of longer-term growth
02/08/24 Chief Medical Officer Robert Kim Sells Shares of 4D Molecular Therapeutics Inc
02/06/24 4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
02/05/24 4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
02/05/24 4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'
02/03/24 4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
01/29/24 4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
FDMT Chatroom

User Image bubbybubster Posted - 13 hours ago

$XBI rotated 20% of my portfolio out of energy to go heavy-weight on biotech last week. good move $FDMT $BBIO $SRRK

User Image Stock_Titan Posted - 20 hours ago

$FDMT 4DMT Announces Presentations at ARVO 2024 Annual Meeting https://www.stocktitan.net/news/FDMT/4dmt-announces-presentations-at-arvo-2024-annual-oqtxqvok08iy.html

User Image Fullratio Posted - 04/25/24

Healthcare sector stocks with high YoY gross profit growth in Q4 2023: $CLSD $FDMT $BEAM

User Image jewell69 Posted - 04/23/24

$LEGN just bot 100 at 36.30 just 2 b prudent, canceled buy order of 201 $FDMT at 25.04

User Image jewell69 Posted - 04/23/24

$FDMT tryin 2 buy 201 at 25.04

User Image jewell69 Posted - 04/22/24

04/22/2024 15:48:59 Sold 200 FDMT @ 26.3101 5,261.95 0.00 0.07 04/17/2024 10:12:13 Bought 200 FDMT @ 26 -5,200.00 $FDMT Grandpa calls it a pyrrhic victory. Not sure what that means, but it doesnt sound good. new topic $BABA 04/22/2024 11:27:55 Sold 200 BABA @ 70.1301 14,025.88 0.00 0.14 04/16/2024 09:33:06 Bought 200 BABA @ 70 -14,000.00

User Image bubbybubster Posted - 04/22/24

top biotechs with upcoming catalysts and promising pipelines $BBIO $FDMT $SRRK

User Image bubbybubster Posted - 04/22/24

$FDMT got another 3k shares under 25. 6k shares @ 26.66 average

User Image Fullratio Posted - 04/19/24

Healthcare sector stocks with high YoY revenue growth in Q4 2023: $FDMT $PAVM $BEAM

User Image insiderbuyingselling Posted - 04/18/24

$FDMT new insider selling: 1750 shares. http://insiderbuyingselling.com/?t=FDMT

User Image DameWave Posted - 04/18/24

$FBIO FBIO is eligible to receive up to ~$140 M in potential late-stage development, regulatory and sales milestone payments plus royalties from $FDMT after the Aevitas Therapeutics deal. Keep an eye on their promising R100 platform in ophthalmology and especially 4D-175 that the deal is about. $XBI https://seekingalpha.com/news/4089674-4d-molecular-therapeutics-new-overweight-barclays-genetic-medicine-platform

User Image jewell69 Posted - 04/16/24

Ms gena Wang "assigned" $FDMT after hours gtc tryin 2 buy 26. 00 4/16 close 26.75 her pt 45 tipRanks says stron buy 10 buys, 0 holds, 0 sells

User Image traderstatusquo92 Posted - 04/09/24

$FDMT buyer in low $20’s

User Image bubbybubster Posted - 04/04/24

$FDMT bought the dip. 2000 shares @ 28.50 to start

User Image insiderbuyingselling Posted - 03/29/24

$FDMT new insider selling: 5833 shares. http://insiderbuyingselling.com/?t=FDMT

User Image Stock_Titan Posted - 03/28/24

$FDMT 4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis https://www.stocktitan.net/news/FDMT/4dmt-announces-update-on-regulatory-interactions-and-development-g2qu5csoqfob.html

User Image Gmo_ Posted - 03/27/24

$FDMT long hold this will continue higher

User Image StockInvest_us Posted - 03/25/24

Signal alert: $FDMT - Overbought Trend Short (Overvalued) https://stockinvest.us/l/c5llwcwWrw

User Image StockConsultant Posted - 03/17/24

$FDMT 4D Molecular Therapeutics stock, solid breakout , see https://stockconsultant.com/?FDMT

User Image AnomalyDetective Posted - 03/15/24

Week 12 MDA picks have just been released for members with 1 out 4 picks already up over 12.4% from selection despite rising negative Momentum Gauge® values in warning signal for markets at http://vmbreakouts.com The count of weekly breakout picks gaining over 10% continues to 280 weeks. Prior recent picks $LAC $FDMT continue higher but use caution as market outflows are increasing.

User Image vjtweet Posted - 03/04/24

$FDMT long above 30

User Image Pancho_Trader Posted - 03/04/24

$FDMT That VWAP line was getting too obvious

User Image Stock_Titan Posted - 03/04/24

$FDMT 4DMT to Participate in Upcoming Investor Conferences https://www.stocktitan.net/news/FDMT/4dmt-to-participate-in-upcoming-investor-4vc8cuqytcn8.html

User Image insiderbuyingselling Posted - 02/29/24

$FDMT new insider selling: 1909 shares. http://insiderbuyingselling.com/?t=FDMT

User Image Stock_Titan Posted - 02/29/24

$FDMT 4DMT Reports Full Year 2023 Financial Results and Operational Highlights https://www.stocktitan.net/news/FDMT/4dmt-reports-full-year-2023-financial-results-and-operational-5z4hupgnzo2v.html

User Image AnomalyDetective Posted - 02/26/24

Week 9 MDA picks up +7.90% through Monday morning with 2 of 4 picks for members up over 10% to start the week and sample pick $FDMT was also in Week 48 selections now up +130% as the Week 48 MDA picks are all positive currently up +175.5% led by $CLSK +300.4%. Daily breakout picks here: vmbreakouts.com Weekly MDA breakout picks and much more here: https://seekingalpha.com/marketplace/1201-value-momentum-breakouts/subscribe

User Image MrMathematical Posted - 02/23/24

$FDMT This damn thing just might pass 30 in a day or two after all. Would love to get my money back.

User Image biotech Posted - 02/23/24

#Fabry Highlights WORLDsymposium™ 2024 with Dr Robert Hopkin Hopkins speaks about Fabry GT: $FDMT on Clinical hold , damages kidney $SGMO high levels of enzyme production, no complications , no need for interventions high levels of expression longest patients data are about 3 years .. and no decrease of expression ! improved pain , QL improved had positive effects of biomarkers + + + starting @ minute 50: https://www.youtube.com/watch?v=jknTkbXeN3o&t=2998s

User Image Bullseye320 Posted - 02/17/24

@MrMathematical yes I will be watching it too. It meets my criteria for a tute pump except that it's not a succesful trial news but an fda approval news so that 1 criteria may make a difference however if price upgrades comes on or before Tuesday means tute getting ready to pump this. $FDMT was great play first 2 days of the news as the price pushed up after that I moved on and waiting for the next similar set up now. 👍👍👍💰

User Image MrMathematical Posted - 02/17/24

@Bullseye320 $IOVA Very interesting observation. Will watch for a pump. I'm long with $FDMT and still waiting for that to recover. It's heavily tute owned but I don't think that makes a lick of difference.

Analyst Ratings
RBC Capital Outperform Apr 15, 24
Barclays Overweight Apr 15, 24
BMO Capital Outperform Apr 1, 24
Jefferies Buy Apr 1, 24
HC Wainwright & Co. Buy Mar 1, 24
BMO Capital Outperform Feb 5, 24
RBC Capital Outperform Feb 5, 24
RBC Capital Outperform Jan 29, 24
Cantor Fitzgerald Overweight Oct 24, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Kirn David Chief Executive Offi.. Chief Executive Officer Jan 23 Sell 18.4079 5,696 104,851 1,151,154 01/25/24
VIKING GLOBAL INVESTORS LP 10% Owner 10% Owner Jan 04 Sell 19.53 540,000 10,546,200 4,247,914 01/05/24
Bizily Scott Chief Legal and HR O.. Chief Legal and HR Officer Jun 08 Sell 20.85 3,750 78,188 1,737 06/12/23
Bizily Scott Chief Legal and HR O.. Chief Legal and HR Officer Jun 08 Option 8.04 3,750 30,150 5,487 06/12/23
Bizily Scott Chief Legal and HR O.. Chief Legal and HR Officer Jun 01 Sell 18.31 2,247 41,143 1,737 06/06/23
Bizily Scott Chief Legal and HR O.. Chief Legal and HR Officer Jun 01 Option 6.49 1,875 12,169 3,984 06/06/23
Moretti August J Chief Financial Offi.. Chief Financial Officer May 15 Option 9.41 3,000 28,230 11,045 05/16/23
Bizily Scott Chief Legal and HR O.. Chief Legal and HR Officer Apr 21 Sell 20 3,750 75,000 2,109 04/25/23
Bizily Scott Chief Legal and HR O.. Chief Legal and HR Officer Apr 21 Option 8.04 3,750 30,150 5,859 04/25/23
Chacko Jacob Director Director Apr 21 Sell 20.05 5,000 100,250 04/25/23
Chacko Jacob Director Director Apr 21 Option 9.41 5,000 47,050 5,000 04/25/23
Kirn David Chief Executive Offi.. Chief Executive Officer Feb 21 Sell 20.88 34,446 719,232 1,859,153 02/23/23
Kirn David Chief Executive Offi.. Chief Executive Officer Jan 19 Sell 20.11 19,524 392,628 1,893,599 01/23/23
Moretti August J Chief Financial Offi.. Chief Financial Officer Dec 21 Option 9.41 3,000 28,230 6,595 12/22/22
Kirn David Chief Executive Offi.. Chief Executive Officer Dec 15 Sell 23.44 86,877 2,036,397 1,913,123 12/19/22
Bizily Scott Chief Legal and HR O.. Chief Legal and HR Officer Dec 01 Option 7.27 5,625 40,894 6,607 12/05/22
Bizily Scott Chief Legal and HR O.. Chief Legal and HR Officer Dec 01 Sell 23.22 6,000 139,320 2,482 12/05/22
SCHAFFER DAVID Director Director Oct 20 Sell 31.19 36,285 1,131,729 901,215 10/22/21